Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex

A Dijkstra, J M Vonk, H Jongepier, G H Koppelman, J P Schouten, N H T ten Hacken, W Timens, D S Postma

Background: Inhaled corticosteroids (ICS) provide short term benefits in asthma but the long term effects are still unknown.

Methods: 281 patients diagnosed with moderate to severe asthma in 1963–75 were re-examined in 1991–9. Information was collected on forced expiratory volume in 1 second (FEV1), bronchial hyperresponsiveness, atopy, smoking, use and dosage of oral and ICS. Patients were included in the analyses if they had at least three FEV1 measurements during two consecutive years after the age of 30 and used ICS during follow up.

Results: Analyses were performed on 122 patients. During a median follow up period of 23 years, 71 men and 51 women had on average 37 and 40 individual FEV1 measurements, respectively. Linear mixed effect models showed that men had a mean annual decline in FEV1 of 20.6 ml/year less after ICS initiation than before (p = 0.011), and in women the decline in FEV1 was 3.2 ml/year less (p = 0.73). In individuals with ≤5 pack years of smoking the decline in FEV1 was 36.8 ml/year less after ICS institution in men (p = 0.0097) and 0.8 ml/year less in women (p = 0.94), the difference between the sexes being significant (p = 0.045). These effects were not observed in those with ≥5 pack years smoking. A higher daily dose of ICS was associated with a smaller decline in FEV1 in men (p = 0.006), an effect not observed in women.

Conclusion: Treatment with ICS in adult patients with moderate to severe asthma was associated with a reduction in the decline in FEV1 over a 23 year follow up period in men who had smoked ≤5 pack years. This effect was dose dependent and was not present in women or in men with ≥5 pack years of smoking at follow up. The lack of effect of ICS on the decline in FEV1 in women needs further study.
FEV1 levels (i.e. intercepts) were made for the periods before maintenance medication was stopped for the appropriate time.19 Oral corticosteroids during the previous 6 weeks. Main-
testing, participants had no exacerbation and had not used oral corticosteroids during the previous 6 weeks. Maint-
ance medication was stopped for the appropriate time.19

After initial testing, subjects generally had routine check-
ups for their asthma at least once a year. Data on lung function and corticosteroid use during check-ups were extracted from the medical records. Lung function was tested with a water sealed spirometer throughout the follow up period (Lode Spirograph D53, Lode Instruments, Groningen, the Netherlands). Lung function data during hospital admis-
sions, asthma exacerbations, or pregnancies were not used.

The dose of inhaled corticosteroids was calculated to an equivalent daily dose of beclomethasone—that is, 500 μg fluticasone, 1000 μg budesonide, and 500 μg budesonide via Turbuhaler being equipotent to 1000 μg beclomethasone.21

Statistical analyses

Linear mixed effect models on FEV1 were used to investigate the effect of the use of inhaled corticosteroids on the annual decline in FEV1.24 The age of 30 was the starting point of the analyses since the maximum lung function level would be achieved before that age and lung function is considered to be in the decline phase.25 Following the methodology described by Naumova et al,26 time was defined as the time relative to the start of inhaled corticosteroid treatment in years. Separate estimations of the annual FEV1 decline and FEV1 levels (i.e. intercepts) were made for the periods before and after the start of inhaled corticosteroid treatment by including the variables time, inhaled corticosteroid use, and their interaction. Furthermore, individual variations in these declines and intercepts were accounted for by estimating the random effects for these variables. Effect modification by sex was incorporated in the model by adding the interaction between time, inhaled corticosteroid use, and sex. Other explanatory variables in the model were height (centred at 1.75 m), first available FEV1 after age 30 (FEV1 centred at 2.8 l, called “FEV1 at age 30”), and their interaction with time, pack years of smoking, and oral corticosteroid use. The latter two variables were time varying. Since including the level of the FEV1 at age 30 and their interaction with time could introduce bias due to regression to the mean, random effects were also estimated for these variables. The results of these analyses indicated that there was no regression to the mean bias—that is, the estimates of the variables in the model did not change and the model fit was not better and therefore the results are presented without these random effects. Several within-subject correlation structures were investigated but none of these gave a better fit than the independent within-subject correlation. To investigate possible effect modification by smoking on the effect of inhaled corticosteroid use on FEV1 decline, the analysis was stratified by pack years of smoking (<5 and ≥5 pack years) at re-

examination. Additional potential risk factors were intro-
duced in the model one at a time—that is, severity of bronchial hyperresponsiveness to histamine at initial testing, number of blood eosinophils, atopy and reversibility (% of predicted) at initial testing and re-examination, total IgE at re-examination, age at introduction of inhaled corticoster-
oids, untreated period (time between the onset of symptoms and the first visit to Beatrixoord), and age at onset of symptoms.

To investigate whether the effect of inhaled corticosteroid use on the annual decline in FEV1 was dose dependent, subjects were divided into a low dose group (<720 μg per day) and a high dose group (≥720 μg per day) based on the median value of individually calculated mean daily doses of inhaled corticosteroids (720 μg per day). This grouping variable was then introduced in the model and separate slopes were fitted before and during the use of inhaled corticosteroids for the two dose groups. To avoid a four-way interaction and the difficulties in interpreting this (dose group * time * inhaled corticosteroid use * sex), analyses were stratified by sex.

To be able to make valid interpretations of the results, individual FEV1 series had to meet basic criteria to be included in the analyses. Firstly, subjects who never used inhaled corticosteroids were excluded. Secondly, subjects had to have three or more FEV1 measurements over a period of at least 2 years in which they did not use inhaled corticosteroids and/or three or more FEV1 measurements over a period of at least 2 years in which they did use inhaled corticosteroids. In subjects who had measurements both with and without inhaled corticosteroids, the earliest measurements should be without inhaled corticosteroids and the later with inhaled corticosteroids. If subjects started using inhaled corticoster-
oids but had discontinued the use of inhaled corticosteroids after a few years, all measurements made after the discontinuation were discarded, even if they started again. In subjects who had sufficient measurements without inhaled corticosteroids but fewer than three measurements with inhaled corticosteroids or during less than 2 years, only the measurements without inhaled corticosteroids were included in the model.

All calculations were conducted in S-plus 2000 (Insightful Corporation, Seattle, WA, USA).

RESULTS

Baseline characteristics

The characteristics of the included and excluded individuals are shown in table 1. Included participants were older, were

Table 1 Characteristics of excluded and included subjects

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Excluded subjects (n = 159)</th>
<th>Included subjects (n = 122)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males (%)</td>
<td>99 (62)</td>
<td>71 (58)</td>
</tr>
<tr>
<td>Age of onset of symptoms (years)</td>
<td>2 (2–14)</td>
<td>6 (2–21)</td>
</tr>
<tr>
<td>Mean daily dose of inhaled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>corticosteroids (μg/day)*</td>
<td>720 (426–1116)</td>
<td></td>
</tr>
<tr>
<td>Initial testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>20 (15–28)</td>
<td>28 (21–37)</td>
</tr>
<tr>
<td>FEV1 % predicted post BD (%)</td>
<td>94 (82–104)</td>
<td>85 (68–97)</td>
</tr>
<tr>
<td>BHR &lt; 16.0 mg/ml (%)</td>
<td>87</td>
<td>87</td>
</tr>
<tr>
<td>≥1 positive skin test (%)</td>
<td>98</td>
<td>97</td>
</tr>
<tr>
<td>Blood eosinophils (&gt;10/μl)</td>
<td>385 (220–539)</td>
<td>330 (220–528)</td>
</tr>
<tr>
<td>Reversibility (% predicted)</td>
<td>21 (14–31)</td>
<td>25 (17–33)</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pack years smoking</td>
<td>0.0 (0.0–2.9)</td>
<td>0.1 (0.0–5.6)</td>
</tr>
<tr>
<td>Non/ex/current smokers (%)</td>
<td>50/5/45</td>
<td>49/6/45</td>
</tr>
</tbody>
</table>

Data are presented as median values (interquartile range) unless stated otherwise.

BHR, bronchial hyperresponsiveness; post BD, after administration of bronchodilator.

*Calculated for individuals who ever used inhaled corticosteroids only.

Differences tested by χ2 test (categorical variables) or Mann-Whitney U test (continuous variables).
inhaled corticosteroids in men and women. Significant differences are shown before and after the introduction of inhaled corticosteroids in men and women, and in the effect of corticosteroids (ICS). Data were corrected for level of FEV1 at age 30 (centred at 2.8 l), height (centred at 1.75 m), pack years smoking, and oral corticosteroid use. There were 4663 FEV1 measurements, the median number of measurements per individual being 37 (22–48) in men and 40 (24–54) in women. The median length of the period without inhaled corticosteroids was 9.8 years (6–19) and the median length with inhaled corticosteroids was 13.8 years (8–20). There was a predominance of smoking in men at baseline and at re-examination, otherwise men and women had similar clinical characteristics at baseline. At re-examination, women had a significantly higher FEV1 % predicted post bronchodilator, a higher degree of reversibility, and a lower total IgE level than men. There was no significant difference between men and women with respect to the age at which inhaled corticosteroids were initiated, the daily dose, or the cumulative dose of inhaled corticosteroids used.

### Longitudinal change in lung function

Median FEV1 at the start of the study (age 30 years) was 2.8 litres. The mean (95% CI) annual decline in FEV1 was 36.6 (23.3 to 50.0) ml/year for a man with an FEV1 of 2.8 litres before institution of inhaled corticosteroids. Subjects who never used inhaled corticosteroids had an annual decline in FEV1 of 12.5 (3.7 to 21.2) ml/year. The difference between subjects who never used inhaled corticosteroids and those who later started inhaled corticosteroids was significant (p = 0.0001), the latter group having a more rapid decline.

### Effect of sex

The introduction of inhaled corticosteroids was associated with a significant reduction in the mean annual decline in FEV1 of 12.9 (1.0 to 24.8) ml/year (p = 0.033). When comparing the sexes, the mean annual decline in FEV1 was similar in men and women before introduction of inhaled corticosteroids: 36.6 (23.3 to 50.0) and 24.7 (9.1 to 40.3) ml/year, respectively (p = 0.25, fig 1). After institution of inhaled corticosteroids men had a significantly smaller decline in

---

### Table 2 Characteristics of men and women in study

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Men (n = 71)</th>
<th>Women (n = 51)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of onset of symptoms (years)</td>
<td>6 (2–22)</td>
<td>6 (3–21)</td>
</tr>
<tr>
<td>Untreated period (years)</td>
<td>14 (4–22)</td>
<td>16 (9–25)</td>
</tr>
<tr>
<td>Age at start of inhaled corticosteroid (years)</td>
<td>40 (34–48)</td>
<td>45 (35–53)</td>
</tr>
<tr>
<td>Mean daily dose of inhaled corticosteroids (µg/day)*</td>
<td>794 (527–1129)</td>
<td>618 (400–1114)</td>
</tr>
<tr>
<td>Period of inhaled corticosteroid use (years)</td>
<td>13.6 (7.0–19.4)</td>
<td>14.0 (8.5–20.7)</td>
</tr>
<tr>
<td>Duration of inhaled corticosteroid use (years)</td>
<td>110.1 (47.7–216.0)</td>
<td>88.6 (46.4–155.9)</td>
</tr>
<tr>
<td>Initial testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>27 (21–34)</td>
<td>30 (24–37)</td>
</tr>
<tr>
<td>FEV1 % predicted pre BD (%)</td>
<td>56 (45–71)</td>
<td>56 (39–69)</td>
</tr>
<tr>
<td>FEV1 % predicted post BD (%)</td>
<td>85 (66–97)</td>
<td>87 (68–97)</td>
</tr>
<tr>
<td>BHR &lt;16.0 mg/ml (%)</td>
<td>86</td>
<td>88</td>
</tr>
<tr>
<td>&gt;1 positive skin test (%)</td>
<td>86</td>
<td>88</td>
</tr>
<tr>
<td>Blood eosinophils (&gt;10⁶/l)</td>
<td>34 (237–534)</td>
<td>280 (215–481)</td>
</tr>
<tr>
<td>Reversibility (% predicted)</td>
<td>24 (18–32)</td>
<td>28 (17–33)</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pack years smoking</td>
<td>2.4 (0–7.2)</td>
<td>0 (0–0.5)</td>
</tr>
<tr>
<td>Non/ex/current smokers (%)</td>
<td>34/10/56†</td>
<td>71/0/29</td>
</tr>
</tbody>
</table>

Data are presented as median values (interquartile range) unless stated otherwise.

BHR, bronchial hyperresponsiveness; pre BD, before administration of bronchodilator; post BD, after administration of bronchodilator.

*Calculated for individuals who ever used inhaled corticosteroids only.

Differences tested by χ² test (categorical variables) or Mann-Whitney U test (continuous variables). Significant difference between males and females: tp = 0.0001; tp = 0.035; tp = 0.018; tp = 0.040.

---

![Figure 1](https://www.thoraxjnl.com)  
**Figure 1** Mean annual change in FEV1 in ml/year (with 95% confidence interval) for men and women before and after starting treatment with inhaled corticosteroids (ICS). Data were corrected for level of FEV1 at age 30 (centred at 2.8 l), height (centred at 1.75 m), pack years smoking, and oral corticosteroid use. Significant differences are shown before and after the introduction of inhaled corticosteroids in men and women, and in the effect of inhaled corticosteroids in men and women.
FEV<sub>1</sub> than before (16.1 (8.0 to 24.1) ml/year; p = 0.011) while in women there was no significant difference (21.5 (11.3 to 31.7) ml/year; p = 0.73). The effect of starting treatment with inhaled corticosteroids on the decline in FEV<sub>1</sub> was not significantly different between men and women, the difference in change in FEV<sub>1</sub> decline between the two sexes being 17.4 (−41.4 to 6.5) ml/year (p = 0.15).

The level of FEV<sub>1</sub> improved after the start of inhaled corticosteroids by 132.8 (7.1 to 258.5) ml in men (p = 0.038) and 132.3 (−18.4 to 283.1) ml in women (p = 0.085, fig 2).

Effect of smoking
The decline in FEV<sub>1</sub> before the start of inhaled corticosteroids was not significantly different between men and women with <5 pack years smoking at re-examination: 54.4 (29.5 to 79.2) and 27.3 (7.6 to 46.9) ml/year, respectively (p = 0.096, fig 1). In men with <5 pack years smoking, the mean decline in FEV<sub>1</sub> changed from 54.4 (29.5 to 79.2) ml/year to 17.7 (6.5 to 28.7) ml/year after the start of inhaled corticosteroids, the difference of 36.8 ml/year being significant (p = 0.0097). In women the values were 27.3 (7.6 to 46.9) ml/year and 26.5 (15.8 to 37.1) ml/year respectively; this difference was not significant. Inhaled corticosteroids reduced the decline in FEV<sub>1</sub> significantly more in men than in women (by 36.0 (0.9 to 71.0) ml/year more in men (p = 0.045)). This positive effect of inhaled corticosteroids was not observed in individuals with ≥5 pack years smoking. The decline in FEV<sub>1</sub> before and after institution of inhaled corticosteroids was 27.8 (14.3 to 41.3) ml/year and 16.1 (3.3 to 28.9) ml/year in men, and 24.5 (3.1 to 52.0) ml/year and 11.6 (17.7 to 41.0) ml/year in women, respectively. The decline in FEV<sub>1</sub> before and after starting treatment with inhaled corticosteroids did not differ between men and women (1.1 (−46.4 to 48.5) ml/year; p = 0.96).

Dose-response effect of inhaled corticosteroids
There was no significant difference in FEV<sub>1</sub> decline before and after institution of inhaled corticosteroids in men who used <720 µg/day (median daily dose used): 14.5 (−11.4 to 40.5) ml/year before and 23.6 (11.8 to 35.3) ml/year after initiation of inhaled corticosteroids (p = 0.51, fig 3). In men who used ≥720 µg/day the decline in FEV<sub>1</sub> after introduction of inhaled corticosteroids was 39.8 ml/year less than before introduction (p = 0.0004). Men who used ≥720 µg/day inhaled corticosteroids had significantly less deterioration in FEV<sub>1</sub> than men using <720 µg/day (48.8 ml/year less decline; p = 0.006, fig 3). This effect was not seen in women.

Risk factors for lung function decline
No additional association was observed with age at onset of symptoms, age at start of inhaled corticosteroids, untreated period, bronchial hyperresponsiveness at initial testing, number of blood eosinophils, total IgE levels, atopy, or reversibility (% predicted).

DISCUSSION
We present the results of a 23 year follow up study in adult patients who had longstanding asthma at the time inhaled corticosteroids became available in the Netherlands (1974), and who had moderate to severe asthma. The results show that both men and women had a comparable decline in lung function before the institution of inhaled corticosteroids. In men the use of inhaled corticosteroids was significantly associated with a reduction in the annual decline in lung function, a finding not observed in women. The beneficial effect of inhaled corticosteroids was dose dependent and was not present in men with >5 pack years smoking.

We are aware that our study is observational in nature and that there is a possibility that the lack of significance of inhaled corticosteroids in women is a spurious effect. Can we, based on our observations, advise not to prescribe inhaled corticosteroids to women with asthma? Firstly, inhaled corticosteroids are beneficial to almost all asthmatics of both sexes by their well known short term (up to 3–5 years)
improvement in lung function, an effect also observed in our study in both men and women. Moreover, inhaled corticosteroids improve symptoms, exacerbation rate, and quality of life in short term studies. Therefore, our study in no way implies that women should not be prescribed inhaled corticosteroids. However, given these short term beneficial effects, one cannot simply evaluate in a double blind randomised study whether inhaled corticosteroids prevent the decline in lung function in asthma over many years. Our data are therefore the best available long term data to date.

Our 23 year follow up study attempted to evaluate whether inhaled corticosteroids prevent lung function loss in asthma. We therefore had to exclude patients who had never used inhaled corticosteroids. We are aware that excluding these patients could lead to some unintended bias, but this group was not the aim of our cohort study. As expected, we found that those not using inhaled corticosteroids at all had better lung function at initial testing and a less rapid decline in FEV₁ over time, probably because they had milder disease. Whether they would also have benefited from inhaled corticosteroids in the long term could not be addressed by our study.

Asthma is generally a benign disease. However, it is acknowledged that lung function may decline more rapidly than in healthy individuals, probably as a result of an ongoing chronic inflammatory airway disease. It is therefore of interest to assess whether anti-inflammatory agents may prevent accelerated loss in lung function. Double blind studies in mild to severe asthma have consistently shown their beneficial effects over short periods of time, although some studies have failed to show this. Our study indicates that an accelerated loss in lung function may indeed occur in asthma which may be reduced by long term treatment with inhaled corticosteroids. Beneficial effects of inhaled steroids have been reported in newly diagnosed asthma with respect to lung function over longer periods of time. Interestingly, we show that this treatment may also be of benefit in individuals with longstanding asthma. Previous (relatively) short term studies did not stratify for sex to assess whether women and men have different responses to inhaled corticosteroids. Our study shows that the observed beneficial effect of this treatment with respect to long term decline in FEV₁ is present in men but not in women in moderate to severe asthma. This is consistent with a recent double blind study in 52 asthmatics (26 placebo) which showed that bronchial hyperresponsiveness improved approximately threefold more in men than in women after 6 weeks of treatment with 2000 μg fluticasone propionate.

It is not clear why the use of inhaled corticosteroids is not associated with a reduced decline in lung function in women. There are several possible explanations. Female sex hormones may play a role. Progesterone has steroid-like anti-inflammatory actions, whereas oestrogens augment inflammation by influencing lymphocyte and monocyte numbers, increasing B cell differentiation and antibody production, and decreasing T cell suppressor activity. Furthermore, oestrogens enhance eosinophil adhesion to human vascular endothelial cells. To what extent sex hormones interfere with the response to inhaled corticosteroids in humans is as yet unknown. Women are reported to have severe asthma more frequently than men. However, the women in our study had similar numbers of blood eosinophils and severity of bronchial hyperresponsiveness as the men, both at initial testing and re-examination, and they had higher FEV₁% predicted post bronchodilator and lower IgE levels at re-examination than men. Differences in asthma severity cannot therefore explain the smaller effect of inhaled corticosteroids in the women in our study. It is also unlikely that a lower prescribed dose of inhaled corticosteroids would account for the difference between the sexes as we found neither a difference in the daily dose nor in the cumulative dose of inhaled corticosteroids used by men and women. The observed lack of effect may also have been due to different airway deposition of inhaled corticosteroids in women than in men. Women have a smaller airway calibre than men, which may enhance deposition of inhaled corticosteroids in the large airways. This may reduce the overall beneficial effect since the current thinking is that peripheral airways contribute significantly to airway obstruction in asthma. Finally, women had a somewhat smaller decline in lung function before initiation of inhaled corticosteroids, although the difference was not significant. It may well be that women with a more rapid decline in lung function would have benefited from treatment with inhaled corticosteroids. This cannot be ascertained from our observations.

Our study shows a dose-response effect of inhaled corticosteroids on the annual decline in FEV₁ in men. An additional analysis showed that this effect was not driven by the effect of smoking. Only 40% of the men using ≥720 μg/day smoked ≤5 pack years at follow up. When women were treated with inhaled corticosteroids, no difference was seen between the effects of low or high doses. This may simply be due to the smaller number of women under study, or it might suggest that women require higher doses of inhaled corticosteroids or have lower compliance rates with maintenance treatment. It is important to clarify these issues because it is well established that inhaled corticosteroids are accompanied by side effects at high doses. Whatever the reason for the underlying differences between women and men, an important message from our results is that studies investigating the effects of inhaled corticosteroids should investigate the effects in men and women separately.

An interesting and important observation is that smoking interferes with the long term beneficial effect of inhaled corticosteroids on the decline in FEV₁ in men. It has been shown previously that smoking is accompanied by a smaller clinical benefit from inhaled corticosteroids. Although the underlying mechanisms are not yet resolved, it may well be that cigarette smoking reduces histone deacetylase-2 expression and activity in the airway wall and alveolar macrophages, thereby reducing the effect of inhaled corticosteroids. The effect of inhaled corticosteroids in men who smoked ≤5 pack years cannot be simply explained by changes in smoking habits. Only four of the 28 men who had smoked ≤5 pack years at the end of the study were smokers at the beginning of the analyses on FEV₁ decline (at age 30) and quit smoking 2–10 years before the introduction of inhaled corticosteroids. The other men were never smokers or ex-smokers and did not start or restart smoking during follow up.

In conclusion, inhaled corticosteroids are not only beneficial in asthma in the short term, but their long term use in moderate to severe adult asthma is associated with a smaller decline in FEV₁ in men in a dose dependent manner. In women there was no effect on the decline in lung function. Since similar doses of inhaled corticosteroids were used in men and women, further studies are needed to investigate whether female sex hormones, airway geometry, deposition and particle size of inhaled corticosteroids, and/or differences in compliance may explain the difference in response between the sexes. Importantly, in men with >5 pack years of smoking, the long term beneficial effects on FEV₁ decline were absent. All efforts should be made to motivate people with asthma to refrain from smoking, particularly since it prevents the long term beneficial effects of the best treatment currently available.
ACKNOWLEDGEMENTS
The authors thank the lung function staff of Beatrixoord Haren for their effort in preparing the database on lung function which was used throughout this study.

Authors’ affiliations
A Dijkstra, H Jongepier, Department of Pulmonary Rehabilitation, Beatrixoord, Haren, University Medical Center and University of Groningen, the Netherlands
A Dijkstra, H Jongepier, N H ten Hacken, D S Postma, Department of Pulmonology, University Medical Center and University of Groningen, the Netherlands
J M Vonk, J P Schouten, Department of Epidemiology and Statistics, University Medical Center and University of Groningen, the Netherlands
G H Koppelman, Beatrix Children’s Hospital, University Medical Center and University of Groningen, the Netherlands
W Timens, Department of Pathology and Laboratory Medicine, University Medical Center and University of Groningen, the Netherlands

This study was supported by the Netherlands Asthma Foundation (grant AF 3.2.00.38).

Competing interests: none declared.

REFERENCES